GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer
Abstract Background The interferon-induced protein known as guanylate-binding protein 2 (GBP2) has been linked to multiple different cancer types as an oncogenic gene. Although the role of GBP2 in cancer has been preliminarily explored, it is unclear how this protein interacts with tumor immunity in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-023-11308-0 |
| _version_ | 1797452329914466304 |
|---|---|
| author | Yunfei Wang Jiadong Pan Fangmei An Ke Chen Jiawei Chen He Nie Yanping Zhu Zhengtao Qian Qiang Zhan |
| author_facet | Yunfei Wang Jiadong Pan Fangmei An Ke Chen Jiawei Chen He Nie Yanping Zhu Zhengtao Qian Qiang Zhan |
| author_sort | Yunfei Wang |
| collection | DOAJ |
| description | Abstract Background The interferon-induced protein known as guanylate-binding protein 2 (GBP2) has been linked to multiple different cancer types as an oncogenic gene. Although the role of GBP2 in cancer has been preliminarily explored, it is unclear how this protein interacts with tumor immunity in gastric cancer. Methods The expression, prognostic value, immune-correlations of GBP2 in gastric cancer was explored in multiple public and in-house cohorts. In addition, the pan-cancer analysis was performed to investigate the immunological role of GBP2 based on The Cancer Genome Atlas (TCGA) dataset, and the predictive value of GBP2 for immunotherapy was also examined in multiple public cohorts. Results GBP2 was highly expressed in tumor tissues and associated with poor prognosis in gastric cancer. In addition, GBP2 was associated with the immune-hot phenotype. To be more specific, GBP2 was positively related to immuno-modulators, tumor-infiltrating immune cells (TIICs), immunotherapy biomarkers, and even well immunotherapeutic response. In addition to gastric cancer, GBP2 was expected to be an indicator of high immunogenicity in most cancer types. Importantly, GBP2 could predict the immunotherapeutic responses in at least four different cancer types, including melanoma, urothelial carcinoma, non-small cell lung cancer, and breast cancer. Conclusions To sum up, GBP2 expression is a promising pan-cancer biomarker for estimating the immunological characteristics of tumors and may be utilized to detect immuno-hot tumors in gastric cancer. |
| first_indexed | 2024-03-09T15:06:58Z |
| format | Article |
| id | doaj.art-b0f068ccb2e34ed095db12824c59b6b0 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-09T15:06:58Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-b0f068ccb2e34ed095db12824c59b6b02023-11-26T13:37:04ZengBMCBMC Cancer1471-24072023-10-0123111110.1186/s12885-023-11308-0GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancerYunfei Wang0Jiadong Pan1Fangmei An2Ke Chen3Jiawei Chen4He Nie5Yanping Zhu6Zhengtao Qian7Qiang Zhan8Departments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityDepartments of Gastroenterology, The Third People’s Hospital of KunshanDepartments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityDepartments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityDepartments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityDepartments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityDepartment of Clinical Laboratory, Changshu Medicine Examination InstituteDepartment of Clinical Laboratory, Changshu Medicine Examination InstituteDepartments of Gastroenterology, Wuxi People’s Hospital, Wuxi Medical Center, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Nanjing Medical UniversityAbstract Background The interferon-induced protein known as guanylate-binding protein 2 (GBP2) has been linked to multiple different cancer types as an oncogenic gene. Although the role of GBP2 in cancer has been preliminarily explored, it is unclear how this protein interacts with tumor immunity in gastric cancer. Methods The expression, prognostic value, immune-correlations of GBP2 in gastric cancer was explored in multiple public and in-house cohorts. In addition, the pan-cancer analysis was performed to investigate the immunological role of GBP2 based on The Cancer Genome Atlas (TCGA) dataset, and the predictive value of GBP2 for immunotherapy was also examined in multiple public cohorts. Results GBP2 was highly expressed in tumor tissues and associated with poor prognosis in gastric cancer. In addition, GBP2 was associated with the immune-hot phenotype. To be more specific, GBP2 was positively related to immuno-modulators, tumor-infiltrating immune cells (TIICs), immunotherapy biomarkers, and even well immunotherapeutic response. In addition to gastric cancer, GBP2 was expected to be an indicator of high immunogenicity in most cancer types. Importantly, GBP2 could predict the immunotherapeutic responses in at least four different cancer types, including melanoma, urothelial carcinoma, non-small cell lung cancer, and breast cancer. Conclusions To sum up, GBP2 expression is a promising pan-cancer biomarker for estimating the immunological characteristics of tumors and may be utilized to detect immuno-hot tumors in gastric cancer.https://doi.org/10.1186/s12885-023-11308-0GBP2Gastric cancerImmunotherapyBiomarker |
| spellingShingle | Yunfei Wang Jiadong Pan Fangmei An Ke Chen Jiawei Chen He Nie Yanping Zhu Zhengtao Qian Qiang Zhan GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer BMC Cancer GBP2 Gastric cancer Immunotherapy Biomarker |
| title | GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| title_full | GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| title_fullStr | GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| title_full_unstemmed | GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| title_short | GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| title_sort | gbp2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer |
| topic | GBP2 Gastric cancer Immunotherapy Biomarker |
| url | https://doi.org/10.1186/s12885-023-11308-0 |
| work_keys_str_mv | AT yunfeiwang gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT jiadongpan gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT fangmeian gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT kechen gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT jiaweichen gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT henie gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT yanpingzhu gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT zhengtaoqian gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer AT qiangzhan gbp2isaprognosticbiomarkerandassociatedwithimmunotherapeuticresponsesingastriccancer |